US FDA declines to approve Vanda's stomach condition drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Vanda Pharmaceuticals (VNDA) Falls 13% After FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
September 19, 2024 8:10 AM EDTVanda Pharmaceuticals (NASDAQ: VNDA) Falls 13% After FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
On September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in... More